Abstract Background Anti‐SARS‐CoV‐2 S antibodies prevent viral replication. Critically ill
COVID‐19 patients show viral material in plasma, associated with a dysregulated host …

Background Millions of people have now been vaccinated against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2). However, it is still unclear which antibody levels …

Background COVID-19 pandemic has generated a million deaths worldwide. The efficiency
of the immune system can modulate individual vulnerability with variable outcomes …

Abstract Background Coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The …

Combined kinetic analysis of plasma SARS-CoV-2 RNAemia, Nucleocapsid (N)-
antigenemia and virus-specific antibodies may help ascertain the role of antibodies in …

The current study aimed at characterizing the dynamics of SARS‐CoV‐2 nucleocapsid (N)
antigenemia in a cohort of critically ill adult COVID‐19 patients and assessing its potential …

Abstract The Nucleocapsid Protein (N Protein) of severe acute respiratory syndrome
Coronavirus 2 (SARS-CoV2) is located in the viral core. Immunoglobulin G (IgG) targeting N …

SARS‐CoV‐2 has emerged as a human pathogen, causing clinical signs, from fever to
pneumonia—COVID‐19—but may remain mild or asymptomatic. To understand the …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and …

More than a year after the start of the pandemic, COVID-19 remains a global health
emergency. Although the immune response against SARS-CoV-2 has been extensively …